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Abstract Combination antiretroviral therapy (CART) has
greatly reduced medical morbidity and mortality with HIV
infection, but high rates of HIV-associated neurocognitive
disorders (HAND) continue to be reported. Because large HIV-
infected (HIV+) and uninfected (HIV−) groups have not been
studied with similar methods in the pre-CARTand CARTeras, it
is unclear whether CART has changed the prevalence, nature,
and clinical correlates of HAND. We used comparable methods
of subject screening and assessments to classify neurocognitive
impairment (NCI) in large groups of HIV + and HIV −
participants from the pre-CART era (1988–1995; N=857) and
CART era (2000–2007; N=937). Impairment rate increased
with successive disease stages (CDC stages A, B, and C) in
both eras: 25%, 42%, and 52% in pre-CART era and 36%,
40%, and 45% in CART era. In the medically asymptomatic
stage (CDC-A), NCI was significantly more common in the
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DOI 10.1007/s13365-010-0006-1CART era. Low nadir CD4 predicted NCI in both eras,
whereas degree of current immunosuppression, estimated
duration of infection, and viral suppression in CSF (on
treatment) were related to impairment only pre-CART. Pattern
of NCI also differed: pre-CART had more impairment in motor
skills, cognitive speed, and verbal fluency, whereas CART era
involved more memory (learning) and executive function
impairment. High rates of mild NCI persist at all stages of
HIV infection, despite improved viral suppression and immune
reconstitution with CART. The consistent association of NCI
with nadir CD4 across eras suggests that earlier treatment to
prevent severe immunosuppression may also help prevent
HAND. Clinical trials targeting HAND prevention should
specifically examine timing of ART initiation.
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Introduction
Since the beginning of the HIV/AIDS epidemic, HIV-
associated neurocognitive disorders (HAND) have been
commonly observed in infected populations (American Acad-
emy of Neurology AIDS Task Force 1991;A n t i n o r ie ta l .
2007). These conditions, ranging from subtle neuropsycho-
logical impairments to profoundly disabling HIV-associated
dementia, are more frequently seen in advanced stages of
HIV disease (AIDS) but can occur even in individuals having
medically asymptomatic HIV infection (CDC 1993 Stage A;
Grant et al. 1987;H e a t o ne ta l .1995; White et al. 1995).
Moreover, HAND confers an increased risk for early
mortality, independent of medical predictors (Ellis et al.
1997a; Mayeux et al. 1993), and often interferes significantly
with cognitively demanding activities of daily living (e.g.,
employment, medication management, driving; Heaton et al.
2004b; Hinkin et al. 2004;M a r c o t t ee ta l .1999, 2004).
The availability of combination antiretroviral therapy
(CART) since 1996 has successfully controlled HIV viremia
andimprovedimmune functioninmanytreated,HIV-infected
(HIV+)patients,leadingtodramaticimprovementsinmedical
morbidity and life expectancy. Clear improvement in neuro-
logical outcomes in the era of CART also has been achieved,
with a significant drop in the rate of frank HIV-associated
dementia (Dore et al. 2003; Robertson et al. 2007;S a c k t o re t
al. 2002). Pre-CART prevalence estimates were approxi-
mately 16% in AIDS cases (McArthur et al. 1993), whereas
more recent estimates are less than 5% (Heaton et al. 2010).
Further benefits of CARTon the broader spectrum of HAND
have been suggested by studies of neurocognitive change in
HIV + groups initiating CART regimens. A recent review of
15 such studies indicated that 11 found some improvement
in neurocognitive test performance after an average of
6 months on CART, although most studies had relatively
small sample sizes and did not control for practice effects on
repeated testing (Joska et al. 2010).
Unfortunately, however, beneficial effects of CART on
neurologic manifestations of HIV infection, especially
H A N D ,h a v eb e e nl e s st h a nc o m p l e t e( M c A r t h u ra n dB r e w .
2010). Neurocognitive responses to CART have been varied
across individuals, and studies of HAND in treated patients
have documented high persisting rates of mild-to-moderate
neurocognitive impairment (NCI). For example, Robertson
et al. (2007) assembled data on 1,160 HIV + patients
involved in 14 different clinical trials involving CART. All
participants completed a brief neurocognitive battery at least
20 weeks after randomization to treatment; 921 participants
completed a follow-up exam 48 weeks later. Prevalence of
NCI was 39% at baseline. Although 44% of those with NCI
at baseline appeared to show CART-related improvement at
follow-up (performed within the “normal” range, but with no
apparent correction for practice effect), 21% of participants
who were NC normal at baseline experienced incident
impairment at follow-up. As a result, the total rate of NCI
at follow-up was not very different from that at baseline
(34% vs. 39%). In another study of persisting NCI on CART,
T o z z ie ta l .( 2007) followed 94 treated patients for a mean of
5 years (multiple assessments). All had NCI at baseline, and
63% showed persisting impairment; however, this could be
an underestimate because, again, it is unclear whether or not
they controlled for practice effects on the neurocognitive
tests. A third recent study reported HAND in 69% of 200
HIV + patients who had maintained good virologic response
(undetectable HIV RNA in plasma on CART) over a median
of 48 months (Simioni et al. 2010).
Causes of continuing high rates of HAND in the CART
era are uncertain, but multiple non-exclusive possibilities
have been suggested: irreversible brain injury prior to
initiating CART, incomplete viral suppression in the central
nervous system (CNS) due to poor CNS penetration of
some commonly used antiretroviral drugs and/or presence
of drug-resistant viral strains, the possibility that even very
low levels of viral replication in the CNS could result in
neural injury or dysfunction due to prolonged exposure to
inflammatory responses and neurotoxic viral proteins,
possible neurotoxicity of antiretroviral therapy (ART)
drugs, and exposure to other conditions that may affect
cognition in long-term survivors, such as increased rates of
metabolic abnormalities and associated vascular pathology
or increased B-amyloid deposition in the brain.
In sum, although the most severe form of HAND, HIV-
associated dementia, appears to be much less common in
the era of CART, questions remain about any long-term
benefit of CART with respect to milder forms of HAND.
These abnormalities remain highly prevalent, and it is
unclear whether their nature, pathophysiological mecha-
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comparison of HAND across time requires consistent
definitions and testing, substantial representative cohorts,
and sufficient knowledge of context including non-HIV
(comorbid) conditions to achieve informative analysis.
This study compares baseline neuropsychological (NP)
and neuromedical findings of two large cohorts of HIV +
and HIV − participants who were recruited and assessed as
part of a long-range program of research coordinated by the
UCSD HIV Neurobehavioral Research Center (HNRC).
Through collaborations with multiple institutions (listed in
the acknowledgements), we performed comparable neuro-
medical and neurocognitive examinations on 857 partic-
ipants from the pre-CART era and 936 from the CART era.
Participants were recruited through advertisements and
outreach to various communities and health care providers.
It should be noted that these were not referral populations
(i.e., not weighted to persons suspected or known to have
neurologic disease). An almost identical NP test battery
covering seven ability domains was used to classify HAND
according to recently published international guidelines
(Antinori et al. 2007). In order to provide comparable
exclusions and minimize the effects of comorbid conditions
on NP results, potential participants in both cohorts were
carefully screened and excluded if they had any history of
significant non-HIV-related risks for cognitive impairment.
Rates of HAND were compared across eras in subgroups
that were stratified by HIV serostatus and clinical stage of
infection (HIV − controls vs. CDC 1993 stages A, B, and
C). (Although the 2008 CDC classification system has de-
emphasized the distinction between historic, asymptomatic,
and mildly symptomatic HIV disease, we included all three
stages in the current analyses to provide links with earlier
studies of HAND and because most of our participants had
been classified before the new guidelines were published
(Centers for Disease Control 2008).) Immunological and
virological predictors of HAND also were assessed and
compared across eras. Finally, to explore possible qualita-
tive differences in neurobehavioral outcomes, we compared
severity and patterns of impairment across the seven ability
domains for HIV + participants from the two eras.
Results
Demographic, psychiatric, and neuropsychological
comparisons of treatment era subgroups
Table 1 displays the demographic characteristics, psychiat-
ric history, and NP status of the treatment era participants,
stratified by HIV serostatus and CDC-1993 disease stage.
Consistent with CDC HIV/AIDS surveillance reports,
demographic differences reflect changes in the US HIV/
AIDS epidemic over time, i.e., the infected population is
somewhat older and contains higher proportions of females
and ethnic minorities, as well as higher proportions of
people reporting any history of injection drug use or who
reported heterosexual contact as their only infection risk
(Centers for Disease Control and Prevention 1992, 1994,
1996, 2000, 2004, 2008). CART era patients also tended to
have slightly lower education levels than pre-CART era
participants. Because classification of NCI was done using
demographically corrected test norms, the demographic
differences between treatment era groups did not bias the
NCI prevalence estimates across time; i.e., there are no
meaningful demographic differences between participant
groups with and without NCI in either treatment era cohort
(see Table 3).
As is typical of HIV + groups and HIV − controls with
similar risk backgrounds, fairly high lifetime prevalence
rates of major depressive disorder and substance use
disorders are observed in both eras; however, fewer
individuals met the criteria for current diagnoses at the
time of testing (i.e., met diagnostic criteria for a DSM-
defined disorder within the last 30 days). Higher rates of
lifetime substance use disorders were seen in the CART era
groups (Table 1), but these conditions were not related to
NCI in the HIV + groups from that era (Table 3).
In both treatment eras, increased rates of NCI are seen
when comparing seronegative controls and subgroups at
successive CDC stages of (historic) HIV disease, in a stair-
step pattern (Fig. 1). Although there are no treatment era
differences in NCI rates among seronegative controls or
infected individuals in CDC stages B and C, impairment
rate among CARTera participants in CDC stage A is higher
than that in their pre-CART counterparts (36.2% vs. 25.2%,
p=0.001). While in the pre-CART era rates of moderate to
severe impairment (consistent with HIV-associated demen-
tia) increased in subgroups with successively more ad-
vanced CDC stages of HIV disease (4%, 12%, and 17% for
CDC stages A, B, and C), this pattern was not seen in the
CART era subgroups (7–8% for all disease stages).
Characteristics of HIV infection and treatment in pre-CART
and CART era HIV + participants
Table 2 shows HIV disease data for infected subgroups.
The participants in both treatment eras who had more
advanced CDC stage reported longer durations of known
infection, but there was a significantly larger (threefold)
difference in estimated disease duration between treatment
era subgroups at each disease stage. Irrespective of disease
stage, the CART era participants had been infected longer,
reflecting improved survival. Patterns of nadir and current
immunosuppression were also significantly different for the
two treatment era cohorts: the CARTera participants tended
J. Neurovirol. (2011) 17:3–16 5Table 1 Pre CART and CART group characteristics by HIV serostatus and CDC stage
HIV- Controls
a
(Group 0)
CDC-A
a CDC-B
a CDC-C
a Within Era Group
Differences
b
N
Pre 179 412 181 85
CART 94 337 216 290
Age
Pre 33.1 (7.8) 31.6 (7.5) 33.7 (6.4) 37.4 (6.9) A<0,B<C
CART 34.8 (11.8) 40.8 (10.2)*** 43.4 (7.4) *** 44.3 (7.7) *** 0<A<B,C
Education
Pre 14.0 (2.5) 13.4 (2.1) 13.2 (2.2) 13.8 (2.0) 0>A,B; B<C
CART 13.0 (2.2) *** 13.3 (2.5) 12.7 (2.4)* 12.9 (2.5)** A>B
% Male
Pre 78.8% 90.5% 85.6% 88.2% 0<A
CART 58.5%*** 81.6% 72.2%** 81.4% 0<B<A,C
% Caucasian
Pre 67.6% 65.0% 71.8% 69.4%
CART 64.9% 43.6%*** 45.4%*** 42.8%*** 0>A,B,C
HIV infection risk – MSM
Pre 49.4% 71.3% 70.2% 77.4% 0<A,B,C
CART 32.2%** 47.3%*** 41.0%*** 39.2%*** A>0,C
HIV infection risk – any IDU
Pre 2.3% 3.9% 6.1% 3.6%
CART 1.1% 12.2%*** 19.5%*** 23.9%*** 0<A<B<C
HIV infection risk – Heterosexual
Pre 43.8% 25.8% 23.8% 19.0% 0>A,B,C
CART 66.7%** 40.4%*** 39.5%** 36.9%** 0>A,B,C
Alcohol Disorder
Lifetime
Pre 32.8% 32.9% 44.5% 46.7% 0<B; A<B,C
CART 19.1%* 50.3%*** 54.4% 60.8%* 0<A<C
Current
Pre 5.4% 4.5% 8.8% 6.2%
CART 2.1% 1.8%* 2.3%** 1.0%**
Other Substance Use Disorder
Lifetime
Pre 26.2% 22.7% 33.1% 40.6% 0<C; A<B<C
CART 19.1% 52.1%*** 65.1%*** 62.5%** 0<A<B,C
Current
Pre 2.7% 3.2% 4.7% 6.2%
CART 5.3% 2.7% 1.4 0.7%* 0>B,C
Major Depressive Disorder
Lifetime
Pre 52.5% 42.2% 57.2% 57.4% A<0,B,C
CART 23.4%*** 44.0% 54.4% 45.1% 0<A,C,B
Current
Pre 6.7% 11.7% 23.6% 21.9% 0,A<B,C
CART 6.4% 11.0% 19.5% 11.8%* 0,A,C<B
Beck Depression
Inventory Total
Pre 5.9 (7.0) 7.7 (7.9) 11.9 (8.9) 11.7 (7.9) 0<A<B,C
CART 5.3 (6.6) 10.2 (9.2) 14.7 (10.5) 13.0 (9.9) 0<A<B,C
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participants with less advanced clinical disease histories (i.e.,
CDC stages A and B). On average, the CARTera participants
in all three disease stages were more likely to be receiving
ARTand had much greater immune improvement (difference
between nadir and current CD4). Also, consistent with
expected differences in treatment effects, being on ART was
associated with a significantly higher (twofold) likelihood of
achieving plasma viral suppression in the CART era (unde-
tectable viral RNA), but not in the pre-CART era. Similar
patternsare seenfor suppression ofHIVincerebrospinal fluid
(CSF) (see Table 2).
Pre-CART vs. CART era associations between NCI
and demographics, psychiatric histories, HIV disease
and treatment characteristics, and everyday functioning
Table 3 addresses possible treatment era differences in
associations between NCI and other variables of interest.
Impaired participants were very slightly older (not a
clinically significant difference), and no other demographic
characteristics (education, gender, or ethnicity), were
associated with impairment. NCI is associated with unem-
ployment, reports of cognitive difficulties in everyday life
(Patient’s Assessment of Own Functioning Inventory), and
Table 1 (continued)
HIV- Controls
a
(Group 0)
CDC-A
a CDC-B
a CDC-C
a Within Era Group
Differences
b
% Employed
Pre 69.6% 80.6% 53.57% 29.8% A>0>B>C
CART 60.2% 44.5%*** 27.8%*** 23.4% 0>A>B,C
PAOFI Cognitive Symptoms
Pre 2.5 (3.1) 2.9 (4.8) 6.0 (7.0) 4.3 (6.1) B>C>A,0
CART 2.5 (4.2) 4.2 (6.1) 5.1 (6.0) 5.4 (6.7) 0<A,B,C; A<C
% Neurocognitively Impaired
Pre 19.0% 25.2% 42.0% 51.8% 0,A < B,C
CART 16.0% 36.2%** 40.3% 44.8% 0<A,B,C; A<C
% Moderately – Severely NC Impaired
Pre 1.7% 3.6% 12.1% 16.5% 0,A<B,C
CART 2.1% 7.1%* 7.8% 6.9%**
PAOFI=Patient’s Assessment of Own Functioning Inventory
* p < .05; ** p < .01; ***p < .001 for comparisons of pre-CART and CART era subgroups
aAsterisks in these columns reflect significant treatment era differences between pre-CART and CART era subgroups defined by HIV serostatus and CDC
HIV disease stage, using chi square or t-tests, as appropriate.
b Differences in this column (< or >) reflect significant results of “within treatment era” comparisons of subgroups defined by HIV serostatus and CDC
HIV disease stage, using chi-square or Students t-tests as appropriate.
Fig. 1 Neurocognitive impair-
ment in the pre-CART and
CART eras by serostatus and
CDC stage, ***p=0.001
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in both eras.
Associations between NCI and infection risk categories
and psychiatric history differed between the two treatment
era cohorts (Table 3). In the pre-CART cohort, a history of
lifetime (but not current) substance use disorders was
associated with NCI. This association was not found in
the CART era cohort even though those participants had
much higher rates of (mostly remote) alcohol and other
substance use disorders. Indeed, those with NCI in the
CART era were less likely to have prior substance use
disorders (54.9% vs. 61.7% for NC normal; chi-squared=
3.92, p<0.05).
Turning to disease and treatment-related correlates of
NCI, low nadir CD4 counts increased risk for NCI in both
treatment eras. In contrast, impairment was also related to
Table 2 Disease and treatment characteristics of pre-CART and CART HIV+ groups
CDC-A
a CDC-B
a CDC-C
a Within Era Group
Differences
b
N
Pre 412 181 85
CART 337 216 290
Estimated Infection Duration (years)
Pre 2.3 (2.5) 3.5 (2.9) 3.5 (3.4) A<B,C
CART 7.1 (6.0)*** 10.3 (6.0)*** 11.9 (6.0)*** A<B<C
Nadir CD4 (cells/ml)
c
Pre 455 [324-600] 273 [159-430] 40 [12-155] A>B>C
CART 295 [200-400]*** 162 [69-291]** 50 [10-153] A>B>C
% Nadir CD4 < 200 (cells/ml)
c
Pre 6.8% 32.0% 81.2% A<B<C
CART 24.6%*** 59.7%** 84.5% A<B<C
Current CD4 (cells/ml)
c
Pre 485 [344-660] 304 [186-438] 40 [12-161] A>B>C
CART 496 [343-697] 437 [251-616]*** 346 [204-552]*** A>B>C
% CurrentCD4 < 200 (cells/ml)
c
Pre 6.3% 28.6% 80.0% A<B<C
CART 7.8% 17.7%** 24.2%*** A,B,C
CD4 Increase (current – nadir)
c
Pre 36 [0-130] 0 [0-45] 0 [0-5] A>B,C
CART 158 [41-317]*** 234 [80-414]*** 249 [110-410]*** A<B,
C
%o nA R T
Pre 37.9% 59.1% 67.1% A<B,C
CART 52.2%*** 74.1%** 87.2%*** A<B<C
# of ARVs (on treatment only)
Pre 1.0 (0.2) 1.2 (0.41) 1.1 (0.40) A<B,C
CART 3.5 (0.75)*** 3.7 (0.87)*** 3.8 (0.98)*** A<C
% Detectable HIV RNA - Plasma (on ART)
Pre 95.0% 98.0% 96.5%
CART 42.5%*** 43.3%*** 48.4%***
% Detectable HIV RNA - CSF (on ART)
Pre 47.8% 65.5% 37.5% B>C
CART 14.0%*** 19.0%*** 18.6%*
ART=antiretroviral therapy; ARVs=antiretroviral drugs
* p < .05; ** p < .01; ***p < .001 for comparisons of pre-CART and CART era subgroups
aAsterisks in these columns reflect significant treatment era differences between pre-CART and CART era subgroups defined by HIV serostatus and CDC
HIV disease stage, using chi square or t-tests, as appropriate.
b Differences in this column (< or >) reflect significant results of “within treatment era” comparisons of subgroups defined by HIV serostatus and CDC
HIV disease stage, using chi-square or Students t-tests as appropriate.
c Cell counts shown as median (interquartile range)
8 J. Neurovirol. (2011) 17:3–16duration of infection and current degree of immunosup-
pression only in the pre-CART era. Also, although Table 1
indicates that higher rates of NCI were seen with more
symptomatic disease histories (CDC-1993 stages A vs. B
vs. C) in both treatment eras, associations of NC outcomes
with disease history are significant and independent of
nadir CD4 only pre-CART; i.e., when nadir CD4 is
covaried in the analyses, more symptomatic CDC-1993
Table 3 Difference between neurocognitively impaired and normal HIV+ subgroups by treatment era
Pre CART era CART era
NP Normal NP Impaired NP Normal NP Impaired
N 454 224 504 339
Age 32.4 (7.4) 33.9 (7.3) * 42.2 (8.9) 43.3 (8.8)
Education 13.4 (2.1) 13.4 (2.1) 12.9 (2.5) 13.1 (2.5)
% Male 89.8% 87.0% 77.0% 80.6%
% Caucasian 68.5% 65.2% 43.2% 44.5%
% Employed 75.0% 52.5% *** 35.7% 28.9% *
Cognitive Symptoms (PAOFI) 2.8 (4.4) 6.5 (7.5) *** 4.1 (5.5) 6.0 (7.1) ***
Beck Depression Inventory Total 8.0 (7.5) 12.3 (9.5) *** 11.7 (9.7) 13.2 (10.2) *
HIV Infection Risk
MSM only 72.6% 70.0% 46.6% 37.5% *
IVDU 3.1% 5.5% 18.4% 17.8%
Heterosexual only 24.3% 24.5% 35.0% 44.7% **
Psychiatric Diagnoses (current/lifetime)
Lifetime
Alcohol 31.5% 50.9% *** 57.0% 51.9%
Other Substance 24.8% 33.1% * 61.7% 54.9% *
MDD 40.6% 50.6% * 48.0% 45.7%
Current
Alcohol 5.8% 5.6% 2.2% 0.9%
Other Substance 2.9% 5.6% 2.0% 1.2%
MDD 13.6% 20.8% * 12.9% 14.2%
Duration of Infection (years) 2.5 (2.6) 3.4(3.0) *** 9.8 (6.3) 9.3 (6.3)
Nadir CD4
a 390 [236-550] 321 [162-514] ** 198 [62-338] 166 [44-290] **
% Nadir CD4 < 200 18.7% 30.0% * 50.6% 59.6% **
% ART 45.6% 50.4% 66.1% 75.5% **
CDC-A 39.0% 34.6% 50.2% 55.7%
CDC-B 55.2% 64.5% 70.0% 81.6% *
CDC-C 70.7% 63.6% 85.0% 90.0%
# of ARVs (on ART) 1.3 (.33) 1.1 (.35) 3.6 (.90) 3.7 (.89)
Current CD4
a 408 [252-572] 350 [182-552] * 442 [276-608] 425 [253-632]
Current CD4 (on ART)
a 318 [191-427] 268 [119-437] 438 [263-625] 408 [246-629]
% Current CD4 < 200 17.8% 27.7% ** 14.2% 18.6%
% Current < 200 (on ART) 26.7% 37.8% 15.1% 19.6%
CD4 Increase (current – nadir)
a 4 [0-94] 12 [0-101] 199 [64-351] 229 [78-388]
CD4 Recovery (on ART)
a 0 [0-62] 21 [0-120] 269 [137-443] 267 [134-439]
% Detectable HIV RNA – Plasma (on ART) 95.3% (n=85) 98.2% (n=55) 44.1% (n=329) 46.8% (n=254)
% Detectable HIV RNA – CSF (on ART) 46.2% (n=91) 63.6% (n=55) * 17.6% (n=255) 16.8% (n=190)
PAOFI = Patient’s Assessment of Own Functioning; MSM = Men who have sex with men; IVDU = Intravenous drug user; MDD = Major
Depressive Disorder
* p < .05; ** p < .01; ***p < .001
Significant differences are between NCI and NC-normal subgroups within treatment eras, as determined by chi-square or t-test, as appropriate.
a Cell counts shown as median (interquartile range)
J. Neurovirol. (2011) 17:3–16 9disease stages were associated with worse NP Global
Ratings in the pre-CART (F (df=3, 669)=15.8, p<0.0001;
A< B<C) but not in the CART-era cohort (F(df=3, 843)=
1.8, p=0.14). Antiretroviral (ARV) treatment itself was
associated with NCI only in the CART era, but this “effect”
is statistically significant only for CDC stage B. Immune
improvement on treatment (current CD4 minus nadir CD4)
was minimal in the pre-CART era and substantial CART
era, but in neither era was this related to NCI. Treatment
reduced HIV viremia only in the CART era, but successful
viral suppression in plasma did not relate to lower risk of
NCI in either era. Finally, in treated individuals, NCI was
associated with failure to achieve viral suppression in the
CSF in the pre-CART era, but not in the CART era.
Treatment era differences in pattern of impairment across
ability domains
Figure 2 displays the rates of impairment across the seven
major ability domains for the participants with NCI in each
treatment era. NCI in the pre-CART era was more often
characterized by deficits in motor speed/dexterity, speed of
information processing, and verbal fluency, whereas the
learning and executive function domains were more
affected in the CART era.
Discussion
In one of the few prior direct comparisons of HAND in the
pre-CART (n=272) and CART (n=251) eras, Sacktor et al.
(2002) found no significant difference in prevalence rates of
NCI in large but demographically very different cohorts of
HIV + patients who were comparably screened for
comorbidities. However, the high rates of observed impair-
ment (74.3% vs. 76%) may have occurred because both
cohorts were specifically selected for being at high risk for
NCI (low CD4 cell counts and/or clinical evidence of
impairment).
A second previous direct comparison of pre-CART (n=
51) and CART (n=90) era groups was conducted by
Cysique et al. (2004) in Australia. These investigators
studied demographically similar HIV + groups in the same
university clinic, in which participants all had AIDS (i.e.,
CDC stage A3, B3, or C) and were carefully screened for
comorbid conditions but were not selected based upon
perceived risk for NCI. A slightly different test battery was
used with the pre-CART and CART era participants, but the
use of normative standards based upon demographically
matched HIV-uninfected (HIV−) controls from each era
helped assure comparability of impairment classifications.
Rates of NCI in this study were much more typical of
clinical populations selected only for having strict comor-
bidity exclusions and were similar for the pre-CART and
CART groups (41% vs. 39%). Interestingly, NCI patterns
differed between the two groups, suggesting that patterns of
CNS pathology may have changed in the CART era (Joska
et al. 2010).
The current study is most similar to that of Cysique et al.
(2004) in that we assembled groups of participants who
were not selected for being at high risk for NCI from the
two treatment eras. The test batteries and methods for
classifying NCI also were somewhat different in the two
studies, and yet rates of NCI were quite similar for
participants with comparable disease stage (all HIV-
infected participants in the Cysique et al. study had AIDS):
pre-CART rates were 41.1% for the Cysique et al. study
versus 37.4% in the current study, and CART era rates were
38.8% in the Cysique et al. study versus 38.5% in this
study.
The current study extended the findings of prior NCI
comparisons in the two HIV treatment eras by providing
data from large, well-characterized samples of HIV −
controls and HIV + participants across the full spectrum
Fig. 2 NP Domain impairment
in pre-CART and CART era
HIV+ samples with NCI. SIP
speed of information processing,
Learn learning efficiency, Recall
delayed recall, Attn/WM atten-
tion/working memory, Exec
executive function; *p<0.05;
**p<0.01; ***p<0.001
10 J. Neurovirol. (2011) 17:3–16of HIV disease. We found that CART era participants
with medically asymptomatic or minimally symptomatic
disease histories actually had a higher NCI rate than their
pre-CART counterparts. This was true despite the facts
that more CART-era participants who had remained
medically asymptomatic were receiving antiretroviral
therapy and that, as a group, they had comparably mild
degrees of current immunosuppression and were much
more likely to have viral suppression in both plasma and
CSF. Although they had significantly higher rates of
lifetime substance use disorders and longer durations of
infection, treatment era differences in these factors were
present at all disease stages and were unrelated to NCI in
the CART era cohort. We suggest that the most important
difference between CDC-A participants in the two eras
that may have contributed to their different NCI rates is
that participants in the CART era had much lower nadir
CD4 cell counts. The era difference in nadir degree of
immunosuppression (nadir CD4) is much larger for
CDC-A than for the other disease stages, and low nadir
CD4 was a robust predictor of NCI in both treatment
eras. In fact, our finding regarding the importance of a
low nadir CD4 as a risk for HAND has been reported
now in multiple large studies in the USA ( Heaton et al.
2009; Robertson et al. 2007) and other countries (Cysique
et al. 2009; Munoz-Moreno et al. 2008; Tozzi et al. 2005).
The fact that NCI was associated with being on ARTonly
in the CART era raises the question of whether some of the
newer ARV medications may have toxic effects on the CNS.
Although this possibility cannot be ruled out and deserves
further study, it cannot be adequately evaluated in a cross-
sectional study because clinical decisions about when to
initiate treatment are based upon indicators of disease severity
(nadir CD4 and medical symptoms) that themselves are risks
for NCI.Inany event,the increasedrate ofNCI among CART
era (vs. Pre-CART) participants who were medically asymp-
tomatic (CDC stage A) cannot be explained by neurotoxic
effects of ARVs because NCI was not significantly related to
treatment status in these individuals.
There were intriguing shifts between pre-CART and CART
eras when we focus on more severe NCI (i.e., those meeting
Frascati neurocognitive criteria for HAD; Antinori et al. 2007).
Whereas in CDC stage C disease, the rate of HAD level NCI in
the CARTera was less than half that of the pre-CARTera (6.9%
vs. 16.7%, p<0.01; Table 1) ,t h er a t eo fm o r es e v e r eN C Iw a s
actually higher in the CART era at CDC stage A (7.1% versus
3.6%, p<0.05). It is possible that the fact that CART era CDC
stage As had a greater likelihood of experiencing prior CD4<
200, plus their longer survival with chronic immune stimulation
might be playing a role in increasing their risk for evolving brain
(neurological) complications.
Prior studies in both pre-CART and CART eras have
demonstrated associations between NCI and HIV RNA levels
in the periphery (Childs et al. 1999; Ferrando et al. 1998;
Nath et al. 2008) as well as in the CSF (Brew et al. 1997;
Cysique et al. 2009; Ellis et al 1997b; Letendre et al. 2004;
McArthur et al. 1997). However, recent reports indicate that
viral suppression on treatment is not sufficient to avoid
development or persistence of NCI (Marra et al. 2009;
Simioni et al. 2010). Prior analyses of data from the current
CNS HIV Antiretroviral Therapy Effects Research (CHAR-
TER) cohort (from which our CART era cases were drawn)
suggested that the best neurocognitive outcomes may be
associated with a combination of successful viral response to
CART and absence of historical severe immunosuppression
(nadir CD4<200; Heaton et al. 2010). In the present study,
treated subgroups from neither era demonstrated an associ-
ation between NCI and viral suppression in plasma;
however, non-detectable virus in CSF was a positive
indicator of normal cognitive function in the pre-CART
subgroup only. Our findings support other observations that
certain biomarkers of CNS disease that seemed promising in
the pre-CART era (e.g., CSF viral load) are not so useful in
the CART era (Cysique et al. 2005).
Both our study and the Cysique 2004 study found
treatment era differences in pattern of NCI that might be
consistent with a shift toward more cortical (vs. subcortical
and white matter) involvement in the CART era. A problem
with interpreting these differences as reflecting a shift
toward greater cortical pathology is that the test battery is
not specifically designed to detect such distinctions (e.g.,
more coverage of language and visuospatial functions
would be desirable). Whether such differences in pattern
of NCI are truly related to differences in type or distribution
of HIV-related brain injury will require correlative work
with studies that also employ neuroimaging or postmortem
neuropathological analyses.
The limitations of this study include the fact that we cannot
rule out cohort differences in this study that are unrelated to
HIV or its treatment, especially given the demographic and
HIV risk background differences in these samples, which
mirror differences in the US epidemic over time (Centers for
Disease Control and Prevention 1992, 1994, 1996, 2000,
2004, 2008). However, we attempted to adjust for demo-
graphic effects on neurocognitive test performances by using
the same age-, education-, gender-, and ethnicity-corrected
normative standards. Also, other than a trivial age difference
between impaired and unimpaired participants (statistically
significant only in pre-CART), none of these demographic
variables related to NCI. Similarly, none of the lifetime or
current psychiatric disorders assessed here (MDD and alcohol
or other substance use disorders) were consistently related to
NCI across treatment eras nor was the risk factor of “any IDU
history” (per selection criteria, this was not current and not
complicated by associated significant overdoses or traumatic
brain injuries). Although HIV infection risk backgrounds also
J. Neurovirol. (2011) 17:3–16 11differed between treatment era cohorts, these were unrelated
to NCI in the pre-CART era; in the CART era cohort, having
“only heterosexual contact” was the sole reported HIV risk
factor associated with a higher rate of NCI.
NCI was classified and characterized in our two
treatment era cohorts using a largely overlapping test
battery (11 of 14 individual test measures were the same)
covering the same seven ability constructs and using the
same standardized methods consistent with recently pub-
lished guidelines for diagnosing HAND (Antinori et al.
2007). However, three of the individual test measures did
differ and helped to measure attention/working memory,
processing speed, and executive functioning in somewhat
different ways. On the other hand, each of these ability
domains had at least one common test measure across eras.
To keep the assessments as comprehensive as possible, we
elected to include the three substitute tests in the main
analyses reported here; however, when we excluded these
measures, rates of NCI did not change significantly across
HIV serostatus and disease stage subgroups.
HIV viral loads in plasma and CSF were neither
available nor standard of care throughout much of the pre-
CART era and were not assayed in our research program
until the later part of that era. Also, the limit of detectability
was higher in these earlier assays (400 vs. 50 copies per
milliliter in the CART era studies). As a consequence, we
had very limited viremia and CSF viral load data for the
pre-CART HIV + cohort, and an “undetectable” finding did
not necessarily mean the same thing across treatment eras.
Nevertheless, the availability of these determinations for
pre-CART participants was linked only to timing of the
assessments (no other selection bias). Also, to permit at
least preliminary treatment era comparisons involving viral
suppression on treatment, we retrieved and analyzed all
available stored samples on pre-CART participants to
obtain total sample sizes of 110 (55 each for plasma and
CSF) with NCI and 176 (85 for plasma and 91 for CSF)
without NCI. Impairment rates were similar for the pre-
CART participants with and without viral load determina-
tions, suggesting that the subgroups with viral load data
were fairly representative. The main finding of a pre-CART
association between NCI and failure of CSF viral suppres-
sion on treatment was statistically significant despite the
reduced sample size (total N=138) for this analysis.
In sum, we found high rates of NCI in large HIV +
cohorts tested in the pre-CART and CART eras. The only
significant treatment era difference was in the medically
asymptomatic stage, in which a higher rate and severity of
impairment was seen in the CART era participants. The
latter CART era subgroup also had the largest discrepancy
(relative to their pre-CART counterparts) in nadir CD4 cell
counts. Due to the major degree of immune reconstitution
and viral suppression seen with the CART-treated partic-
ipants, current CD4s and viral loads were no longer
significant indicators of risk for NCI. The fact that low
nadir CD4 was a similarly robust predictor of impairment in
both eras is consistent with the view that early severe
immunosuppression may initiate at least partially irrevers-
ible changes in the CNS and that earlier treatment aimed at
protecting patients from these processes may improve CNS
outcomes (Heaton et al. 2010). In view of the persisting
high rates of NCI in the CART era, especially in HIV +
individuals with a history of low nadir CD4s, clinical trials
are needed to assess the value of initiating treatment in
neurocognitively normal persons before they become
markedly immunosuppressed. This type of longitudinal
study, in which treatment is not linked to evidence of
advancing disease, also may provide the most interpretable
information about potentially neurotoxic effects of ARVs.
Materials and methods
Subjects
Pre-CART subjects were selected from the original cohort of
the HNRC at the University of California San Diego. This
subgroup consisted of 179 HIV-uninfected (HIV−) and 678
HIV-infected (HIV+) participants who had been enrolled into
the HNRC study between December 1988 and December
1995. Exclusionary criteria for these subjects included any
history of neurologic disorders and other conditions (e.g.,
psychiatric disorder with psychotic features, medications with
CNS effects) known to affect neurocognitive performance
HIV seronegative cases for CART era comparisons (n=
94) were selected from a larger group of HIV − subjects
enrolled in the NIDA Program Project “Effects of Meth-
amphetamine and HIV” at the HNRC. Subjects were
enrolled between May 1999 and May 2004 and had the
same exclusion criteria as the pre-CART cases.
TheHIV+CARTsubjects(n=843) in this study were drawn
from the six participating university centers of the CHARTER
study: Johns Hopkins University (Baltimore, MD, n=99), Mt.
Sinai School of Medicine (New York, NY, n=152), University
of California San Diego (San Diego, CA, n=179), University
of Texas Medical Branch (Galveston, TX, n=142), Univer-
sity of Washington (Seattle, WA, n=137), and Washington
University (St. Louis, MO, n=134). Subject recruitment
began in September 2003 and ended in August 2007.
While there were no formal exclusion criteria for partici-
pation in the CHARTER study, we utilized the online
supplement to the Antinori et al. (2007) report which
provided detailed guidelines for classifying the most com-
monly encountered comorbid conditions with respect to
whether they should be considered incidental, contributing,
or confounding. The comorbid conditions specifically
12 J. Neurovirol. (2011) 17:3–16addressed in the guidelines include developmental disabil-
ities, alcohol and other substance use disorders, traumatic
brain injuries and other non-HIV-related neurologic con-
ditions, systemic diseases including co-infection with hepa-
titis C virus, and HIV-related opportunistic CNS disease.
Although it was recognized that it would be impossible to
specify how to rate the full range of potential comorbid
conditions and their combinations, the guidelines for the
conditions just mentioned exemplified the following basic
concepts: (1) incidental conditions are those that may affect
neurocognitive performance to a minor degree but would be
unlikely (by themselves) to cause an individual to be
classified as significantly “impaired”; (2) contributing con-
ditions could cause at least mild neurocognitive impairment,
but the severity, nature, and/or timing of the impairment and
associated disability make it likely that the currently
observed impairment and functional decline also represent
significant effects of HIV; and (3) confounding conditions
are those that could fully explain significant neuropsycho-
logical impairment and currently observed problems with
everyday functioning; HIVeffects cannot be reliably inferred
in these cases. For the purposes of this study, only those
CHARTER participants deemed to have incidental comor-
bidity (n=843) were used for the CART era HIV + cases.
Procedures
Standard protocol approvals, registrations, and patient
consents
These procedures were approved by the Human Subjects
Protection Committees of each participating institution. Writ-
ten informed consent was obtained from all study participants.
Neuromedical examination
Neuromedical examination procedures included medical
history, structured neurological and medical examination, as
well as collection of blood and urine samples. These
procedureswereperformedbyphysicians,nurse practitioners,
ortrainednursesandresearchassociates.Thestaff performing
neuromedical and NP assessments was certified by the
coordinating center (University of California, San Diego).
Laboratory assessment
HIV infection was diagnosed by enzyme-linked immunosor-
bent assay with Western blot confirmation. Routine clinical
chemistrypanels,completebloodcounts,rapidplasmareagin,
hepatitis C virus antibody, and CD4+ Tcells (flow cytometry)
were performed at each site’s Clinical Laboratory Improve-
ment Amendments (CLIA)-certified, or CLIA equivalent,
medical center laboratory. HIV RNA levels were measured
centrally in plasma and CSF by reverse transcriptase-
polymerase chain reaction (Roche Amplicor, v. 1.5, lower
limit of quantitation 50 copies per milliliter).
Neurobehavioral examination
All the participants completed a comprehensive neurocogni-
tive test battery, covering seven cognitive domains known to
be commonly affected by HIV-associated CNS dysfunction
(administration time=2–2.5 h; see Table 4 for listing of
Table 4 Tests and Sources of Normative Data for the Neuropsycho-
logical Battery
Cognitive Domain and Test Normative Data
Speed of Information Processing
Digit Vigilance Time
a Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
WAIS-III Digit Symbol Heaton, Taylor, & Manly (Heaton
et al, 2002)
WAIS-III Symbol Search
b Heaton, Taylor, & Manly (Heaton
et al, 2002)
Trail Making Test, Part A Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
Learning and Memory (2 domains)
Story Memory Test Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
Figure Memory Test Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
Abstraction/Executive Functioning
Halstead Category Test
a Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
Wisconsin Card Sorting Test
(64-item)
b
Kongs, Thompson, Iverson, &
Heaton (Kongs et al, 2000)
Trail Making Test, Part B Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
Verbal Fluency
Controlled Oral Word Association
Test
Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a);
(Letters F-A-S/P-M-R for Spanish
speaking Bilinguals)
Artiola et al. (Artiola i Fortuny
et al, 1999)
Category Fluency (Animals) Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
Attention/Working Memory
WAIS-R Digit Span
a Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
WAIS-III Letter-Number
Sequencing
b
Heaton, Taylor, & Manly (Heaton
et al, 2002)
PASAT (1
st channel only) Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
Motor
Grooved Pegboard Test (Dominant
& Non-dominant Hands)
Heaton, Miller, Taylor, & Grant
(Heaton et al, 2004a)
aPre-CART era only;
bCART era only
WAIS-R Wecshler Adult Intelligence Scale-Revised; WAIS III –
Wecshler Adult Intelligence Scale 3
rd Edition; PASAT – Paced Auditory
Serial Addition Task
J. Neurovirol. (2011) 17:3–16 13specific tests). The best available normative standards were
used, which correct for effects of age, education, sex, and
ethnicity as appropriate. Test scores were automatically
converted to demographically corrected standard scores
(T scores) using available computer programs. To classify
presence and severity of neurocognitive impairment, we
applied a published objective algorithm that has been shown
to yield excellent interrater reliability in previous multisite
studies (Woods et al. 2004). This algorithm conforms to the
Frascati criteria for diagnosing HAND (Antinori et al. 2007),
which require presence of the least mild impairment in at
least two of the seven ability domains.
Although the neurocognitive test batteries between the
HNRC (pre-CART era) and CHARTER (CART era) studies
were similar, there were some test substitutions in the
neurocognitive test battery for the CART era subjects. The
WAIS-III Symbol Search Test was used in place of the time
(speed) component of the Digit Vigilance Test; the WAIS-
III Letter Number Sequencing Test was used in place of the
WAIS-R Digit Span Test; and the Wisconsin Card Sorting
Test 64 Card Version was used in place of the Halstead
Category Test. All test substitutions were determined to be
tapping the same cognitive domain as the original test, and
secondary analyses were performed to ensure similar
patterns of findings with respect to NCI rates in treatment
era and CDC stage group comparisons.
Psychiatric examination
Psychiatric diagnoses were assessed using the Structured
Clinical Interview for DSM-IV (SCID; First et al. 1994) for
the pre-CART subjects or the computer-assisted Composite
International Diagnostic Interview (CIDI) (World Health
Organization 1997) for the CART subjects. Both are
structured instruments widely used in psychiatric research.
The SCID and CIDI classify current (within the last
30 days) and lifetime diagnoses of mood disorders and
substance use disorders, as well as other mental disorders.
Current mood was assessed with the Beck Depression
Inventory (BDI) or the Beck Depression Inventory-II (BDI-
II; Beck et al. 1961, 1996).
Functional impairment in everyday life
Reports of cognitive difficulties in everyday life were
assessed using the Patient’s Assessment of Own Function-
ing Inventory (PAOFI; Chelune et al. 1986). The PAOFI
includes 33 items on which participants rate themselves as
having neurobehavioral difficulties in their everyday lives.
Domains of memory, language and communication, senso-
ry–perceptual and motor skills, and higher-level cognitive
functions are assessed. A total summed score is derived,
with higher scores indicating more difficulty.
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